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Graves’ Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves’
disease (GD). Its ultimate cause remains unclear, but it is commonly considered an
autoimmune disorder due to self recognition of autoantigens constitutively expressed
by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous
glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and
active GO. However, based on the complex pathogenesis of GO, a number of factors
may have a protective and maybe a therapeutic role. The use of other medications
improving the effect of GC may increase the overall effectiveness of the therapy and
reduce GC doses, thereby limiting side effects. Recently, a possible protective role of
3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, the so-called statins, and
perhaps of lowering cholesterol levels, has been proposed. Thus, statins have been
reported to be associated with a reduced frequency of GO in GD patients and in recent
cross-sectional and retrospective studies a significant correlation was found between the
occurrence of GO and both total and LDL-cholesterol in patients with a GD of relatively
recent onset, suggesting a role of cholesterol in the development of GO. Moreover,
a correlation was found between the GO clinical activity score and total as well as
LDL-cholesterol in untreated GO patients, depending on GO duration, indicating a role
of cholesterol on GO activity. Therefore, statin treatment may be beneficial for GO. Here
we review this subject, which offers new therapeutic perspectives for patients with GO.
Keywords: Graves’ orbitopathy, Graves’ disease, thyroid, autoimmunity, statin, 3-hydroxy-3-methylglutaryl-
coenzyme reductase, cholesterol, pleiotropic effects of statins
INTRODUCTION
Graves’ orbitopathy (GO) is a disfiguring syndrome observed in patients with autoimmune
thyroid diseases, especially Graves’ disease (GD). Recognized risk factors for GO development are
uncontrolled hyperthyroidism, radioiodine (RAI) treatment, and smoking. The pathogenesis of GO
is due to a number of complex mechanisms which interplay among each other, namely humoral
and cell-mediated immunity, cytokine production, and oxidative stress. Based on this knowledge, a
number of factors may have a protective andmaybe therapeutic role. Recently, a possible protective
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role of 3-hydroxy-3-methylglutaryl-coenzyme reductase
inhibitors, commonly known as statins, and perhaps of lowering
cholesterol levels, has been proposed. Here we review this
subject which offers new therapeutic perspectives for patients
with GO.
BRIEF NOTES ON GO
GO is generally described as an autoimmune disease and it is
observed in ∼25–30% of patients with Graves’ hyperthyroidism
and less commonly in patients with hypothyroid autoimmune
thyroiditis, or in those without thyroid dysfunction, the so-
called euthyroid GO (1–3). Although the ultimate cause of GO
remains unclear, some of the molecular mechanisms have been
clarified. GO is likely due to an autoimmune reaction against
autoantigens constitutively expressed by orbital fibroblasts (OFs)
and thyroid epithelial cells, being the TSH-receptor the major
autoantigen (1–3). Recently, a major role of the insulin-like
growth factor-1 receptor (IGF-1R) has emerged (4). The extent
to which IGF-1R has an intrinsic role or its actions are related to
its capability of interplaying with the TSH-R has to be clarified
(5). Overall, once the autoimmune reaction is started, both B and
T cells infiltrate the fibroadipose orbital tissue and, through a
number of interconnected events, lead to the cell modifications
underlying the connective tissue remodeling typical of GO, with
orbital fat expansion and extraocular muscle enlargement, which
are ultimately responsible for the clinical manifestations of the
disease (1, 2, 6).
The typical clinical features of GO are proptosis,
inflammation, and diplopia. Subclinical eye involvement is
common, whereas only∼3–5% of patients with GO have a severe
disease characterized by corneal ulceration, severe inflammation,
or compressive optic neuropathy (2, 7). In addition to genetic
and demographical variables (6), the recognized risk factors
associated with the development of GO in GD patients are age,
sex, hypothyroidism, inadequate control of hyperthyroidism,
radioiodine, and cigarette smoking (8–21).
The choice of treatment depends on the extent of GO
activity, which is defined by a clinical activity score (1, 22).
Patients affected with mild GO can be treated with lubricants
and/or selenium (1, 23, 24), whereas, according to the European
Group On Graves’ Orbitopathy (EUGOGO) guidelines, high
dose intravenous glucocorticoids GC (ivGC) are the first line
treatment for moderately severe and active GO (1). However,
more recently, new medications have been proposed, including
rituximab (25), teprotumumab (26, 27), mycophenolate (28),
and tocilizumab (29). Finally, orbital decompression, squint
or palpebral surgery can be considered in patients with an
inactive disease, for therapeutic or rehabilitative purposes
(30). The use of systemic GC takes advantage from their
immunosuppressive and anti-inflammatory actions, resulting
in an overall beneficial effect ranging from ∼35 to ∼80% of
patients (1, 31). Regarding the molecular mechanisms of GC,
their actions on genomic and non-genomic pathways may affect
the production of cytokines, the distribution of circulating
T-cell subsets, the recruitment of monocytes and macrophages,
the expression T-lymphocyte adhesion molecules, as well as
the production, differentiation and homing of dendritic cells
(32–34), thereby blocking the interplay between innate and
adaptive immune responses. Unfortunately, patients are often
selected to treatment because of the severity of the disease,
despite having an inactive GO when immunosuppression is
not effective. Thus, when patients with a long standing, still
severe, but fibrotic and inactive GO are included in studies
on immunosuppressive treatments, the response rate decreases
remarkably. These observations may explain why about ∼30%
of patients do not respond to GC. Another potential explanation
for the lack of response to treatment may be the necessity for a
stronger immunosuppression. The use of additional medications
may in theory improve the effects of GC, possibly increasing
the overall effectiveness of the therapy and reducing GC dosage,
thereby limiting side effects.
STATINS AND GO
Clinical Standpoint
Statins are the most commonly used drugs that improve
cardiovascular risk by reducing low-density lipoprotein (LDL)
cholesterol levels (26, 35). The JUPITER trial assessed the
potential benefit of statins in healthy participants (36, 37),
which was demonstrated by a significant reduction of markers
of systemic inflammation (e.g., C-reactive protein), cholesterol
levels, and the number of cardiovascular events (37, 38).
The study showed the pleiotropic anti-inflammatory actions of
statins, which were not related to their actions in terms of
lowering cholesterol, and suggested that statins can be used as
a new adjuvant anti-inflammatory therapy, in accordance to
various studies (39–50). Statin treatment seems to be linked
with the reduced risk of developing GO among patients with
GD (51). Stein et al. studied a large cohort of patients with
newly-diagnosed GD to identify risk factors associated with the
development of GO, indicating that thyroidectomy as the chosen
treatment of hyperthyroidism and exposure to statins may lower
the risk (51). They investigated whether the administration
of drugs with anti-inflammatory actions reduce the risk of
GO. In a multivariate regression model, medical therapy with
antithyroid medications, regardless of whether it was used alone
or followed by RAI, did not modify the risk of GO compared to
patients receiving RAI alone. In contrast, thyroidectomy alone
or thyroidectomy with antithyroid medications were associated
with a significant reduced risk of GO compared to RAI alone.
Regarding TSH levels, individuals with TSH >7 µIU/mL had a
higher risk of developing GO compared to those with TSH levels
≤7 µIU/mL, but this finding was not statistically significant.
Finally, the authors assessed the potential protective effect on
GO development of COX-2 inhibitors and statins. The use of
statins for at least 60 days during an observation lasting 1 year
was followed by a reduction of GO risk by ∼40%. In contrast,
statistically significant differences in terms of GO risk in patients
exposed to non-statin cholesterol lowering medications were not
found. Furthermore, in both univariate and multivariate models,
no significant differences between subjects treated with COX-
2 inhibitors and subjects not receiving these medications were
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FIGURE 1 | Molecular basis for a role of cholesterol and statins in the pathogenesis of Graves’ Orbitopathy (GO). The symbol ⊣ indicates the pathways inhibited by
statins, namely its pleiotropic effect in the regulation of apoptosis, autophagy, cell growth, and differentiation (left side of the figure), and the reduced synthesis of free
fatty acids (upper sides of the figure). HMG, 3-hydroxy-3-methyl-glutaryl; MTP, microsomal triglyceride transfer protein; VLDL, very low density lipoproteins; HDL, high
density lipoproteins; APO, apolipoprotein; LDL-R, low density lipoprotein receptor; FFAl, free fatty acids; TNFα, tumor necrosis factor α; ROS, reactive oxygen species;
ER, endoplasmic reticulum.
observed (51). The protective action of statins on the risk of
GO was considered as a direct effect of the immunomodulatory
effects of statins (52).
Molecular Mechanisms
As depicted in Figure 1, several studies reported that statins
influence positively tissue remodeling and protect against heart
failure (53, 54). The effects of statins are due to the competitive
inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
reductase, the key-limiting enzyme of cholesterol synthesis in
the multistep mevalonate pathway in the liver (36, 37, 55). In
addition to the biosynthesis of cholesterol, mevalonate is also a
precursor of isoprenoids, namely farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP), and the inhibition
of the synthesis of isoprenoid intermediates plays a major role in
most of the pleiotropic effects of statins (56). The prenyl groups
derived by mevalonate are essential for cell activities, such as
growth and differentiation, because of their role in the post-
translational modification of proteins involved in intracellular
signaling (57–59). Thus, it is demonstrated that statins induce
cell death in many cell types, including macrophages (60, 61)
cardiac myocytes (62), and smooth muscle cells (SMCs) (63–65).
Moreover, the apoptosis induced by statins can be totally blocked
by the addition of GGPP and partially by FPP, suggesting that
geranylgeranylation is a key process for this effect which does not
seem to be related with the reduction of cholesterol (66).
To investigate the effects of blocking the mevalonate pathway
on both extrinsic and intrinsic apoptosis pathways, Ghavami
et al. measured cysteine-dependent aspartate-directed proteases
(caspase) cleavage in human atrial fibroblast (hATF) following
simvastatin treatment for up to 120 h (67). Their data showed
that the activation of the intrinsic pathway is selectively due to
mevalonate cascade inhibition. In particular, through HMG-CoA
inhibition, statins concomitantly induced autophagy, apoptosis,
and unfolded protein response (UPR) stress in the endoplasmic
reticulum (ER) in hATF (67). The initiation of apoptosis is driven
by the disruption of the balance between pro- and anti-apoptotic
proteins. HMG-CoA inhibition also promotes UPR/ER stress, as
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indicated by an increase in the ER of the chaperone and signaling
regulator BIP/GRP78, and by the activation of endoplasmic
reticulum kinase (PERK) and transcription factor 4 (ATF4),
which in turn activate the CCAAT-enhancer-binding protein
homologous protein CHOP to support apoptosis. Inhibition
of HMG-CoA also leads to leak of cathepsin B (CATH-B)
and L (CATH-L) from lysosomes, thereby enhancing apoptosis
(67), and inducing the autophagy flux. These findings suggest
that statins influence autophagic events acting on the co-
regulation of apoptosis and UPR (67). Even if the molecular
mechanisms are not fully clarified, the activity of statins on
these processes may explain, at least in part, their pleiotropic
effects also in GO. Thus, the autophagic and cell death programs,
which influence the innate immune signaling pathway, are
the key elements of the inflammation balance. The “danger
hypothesis” and the intrinsic role of autophagy in GD have
been recently described by Kawashima et al. (68), who suggested
that autophagic events, through the processing and delivery
of cytosolic antigens, enable thyroid cells to present antigens
to CD4+ T cells. Furthermore, autophagy may influence the
differentiation of OFs into mature adipocytes (69), and the early
autophagic flux can also trigger the cell death-cascade in several
cell types, including fibroblasts and monocytoid cells (70). Based
on these assumptions, the association between statin treatment
and an altered autophagy due to a severe reduction of protein
prenylation, reflecting blocking of the mevalonate pathway, may
be a potential explanation for their protective effect on GO. As
reported above, statins induce cell death in human fibroblasts
(67), and it would be interesting to investigate whether this
effect can also influence the production of glycosaminoglycan by
OFs, and their differentiation into adipocytes andmyofibroblasts.
Recently, Shih et al. reported a direct correlation between mast
cells and macrophage infiltration in the Muller’s muscle and the
extent of the upper lid retraction (71). By Masson’s trichrome
staining, they evaluated the proportions of fat, muscle, and
fibrosis in Muller’s muscle specimens. Normal muscle samples
had undulating bundles of smooth muscle fibers, a thin layer
of connective tissue and small deposits of fat. In contrast, GO
Muller’s muscles presented a decreased muscle volume and an
increase in fat tissue and fibrosis (71). The immunohistochemical
study of Muller’s muscle showed that normal samples were
characterized by mast cells and macrophages infiltrating
muscular tissue. In patients with GO the mast cell component
was decreased, and the share of macrophages infiltrating Muller’s
muscle was significantly higher. To investigate to what extent
the decrease in muscle reflected an increase in apoptosis,
Shih et al. performed an immunohistochemical staining for
caspase-3, which was undetectable in all samples, indicating
that apoptosis is not increased and that the reduced muscle
volume in GO Muller’s muscles likely reflects an attenuated
myogenesis, augmented adipogenesis, and transdifferentiation of
myoblasts into adipocytes (71). The regression models showed
that mast cell infiltrating Muller’s muscle correlated positively
with fractional fat composition, and negatively with fractional
fibrosis. Moreover, a direct correlation between macrophage
counts and both fibrosis and extent of the upper eyelid retraction
was observed. Overall, the findings led to the conclusion that
the degree of inflammatory cell infiltration of Muller’s muscle is
associated with the clinical severity of the upper eyelid retraction
(71). Croons et al. demonstrated that statins have the capability of
triggering apoptosis in macrophages, at concentrations at which
SMCs are in contrast resistant (66). Thus, according to the ability
of statins of affecting macrophage viability in vitro by inducing
apoptosis, the early autophagic flux induced by statins may
explain apoptosis of macrophages infiltrating Muller’s muscles in
GO patients, suggesting a beneficial effect of these medications.
A recent study by Shahida et al. showed that Simvastatin
may inhibit adipogenesis in preadipocytes and human OFs,
modulating the expression of early, and late adipogenic genes in
both cell types (72). They used 3T3-L1 preadipocytes and human
OFs, exposing them to 10% cigarette smoke extract (CSE) with
or without Simvastatin, and compared gene expression between
these cells and unexposed cells. In 3T3-L1 preadipocytes, Cyr61,
Ptgs2, Erg1, and Zfp36 levels were greater in cells exposed to
CSE compared with unexposed cells. Interestingly, Simvastatin
downregulated the expression of these genes. Moreover, CSE
alone did not induce adipogenesis, while Scid1, PPAR-γ, and
adipogenesis itself were reduced in preadipocytes treated with
Simvastatin compared to untreated cells. Similar effects were seen
also in human OFs (72).
In addition to the above-mentioned actions, statins seem
to have, at least in vitro and in experimental animal models
of autoimmune diseases, an immunoregulatory action (73–
76), whereas, to our knowledge, there are no reports on the
use of statins in human autoimmune diseases. The main
immunoregulatory action of statins seems to be related to
tolerogenic dendritic cells (TolDCs), a specialized subset
that induces immune tolerance and counteracts autoimmune
responses (74). Atorvastatin, has been shown to induce TolDCs,
thereby ameliorating experimental autoimmune diseases
such as myasthenia gravis and experimental autoimmune
encephalomyelitis (74, 75). In addition, statins may exert an
inhibitory action on antigen-presenting dendritic cells. Thus,
Simvastatin was found to inhibit the maturation of myeloid
dendric cells derived from peripheral blood mononuclear cells
from patients with autoimmune optic neuritis and to counteract
the proliferation of T-cells induced by dendritic cells (76).
CHOLESTEROL AND GO
In addition to a possible direct action of statins on the eye by
their pleiotropic effects, the effects of these drugs in GO may
also reflect lowering of cholesterol serum level (77). In a recent
cross-sectional study, a significant correlation was found between
the occurrence of GO and both total and LDL-cholesterol, in
patients with a GD of relatively recent onset, suggesting a role
of cholesterol in the development of GO (77). Moreover, a
correlation was found between CAS and total as well as LDL-
cholesterol in untreated GO patients depending on GO duration,
indicating a role of cholesterol on GO activity. In the former
population of patients with a GD of recent onset, based on
the presence or absence of GO, cut-off values were established
for total cholesterol at 191 mg/dl and for LDL-cholesterol at
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118.4 mg/dL (77). Cholesterol levels above these values were
associated with a significantly increased risk of GO. Still in the
former population, the percentage of patients with high total
cholesterol was significantly greater in patients with GO (77).
Overall, the fact that the relation between GO and cholesterol
was restricted only to patients with GD of recent onset could be
somehow anticipated. In GD patients, there is a close temporal
relation between the occurrences of hyperthyroidism and GO,
and GO only very rarely appears more than 12 months after
the onset of hyperthyroidism (78). This implies that risk factors
for GO are more readily identified in patients with a GD of
recent onset compared to patients with a long-standing disease,
in whom GO occurrence is a very rare event (78). In this context,
it is interesting to note that the observations of Stein et al.,
who, as mentioned above, found a protective role of statins
in terms of GO development, were obtained in patients with
GD of recent onset (51). In patients with GO, the severity and
activity of the eye disease appeared to be minimally affected by
serum lipids, even though CAS values were significantly higher
in GO patients with high total cholesterol. It is possible that
the findings may have been compromised by the fact that some
patients had undergone intravenous glucocorticoid treatment for
GO before enrollment, with a consequent improvement of GO.
Therefore, the analysis was restricted to untreated GO patients,
and a significant correlation was found by multivariate analysis
with adjustment for GO duration (a variable that correlated with
CAS by univariate analysis) between CAS and both total and
LDL-cholesterol. In this subgroup of patients and in accordance
with the findings obtained in the total cohort of GO patients, CAS
was significantly higher in those with high total cholesterol (77).
Overall, these data suggest the possibility that not only cholesterol
is a possible GO risk factor, but also that it may be associated with
more active forms of the eye disease.
In confirmation of these data, in a recent retrospective study, it
was reported that patients with GO had higher LDL-cholesterol
and total cholesterol compared with patients affected with GD
without GO. Furthermore, the percentage of patients who had
LDL-cholesterol and total cholesterol levels above the upper
limit of the normal range was significantly and remarkably
greater in patients with GO (79). These observations suggest that
cholesterol is indeed a risk factor for GO.
The mechanisms underlying the potential link between GO
and cholesterol may reflect the known altered inflammatory
state of hypercholesterolemia, as shown in Figure 1. Thus, the
disorders of lipid profile are associated with a mild-to-moderate,
systemic, chronic inflammation (36, 37). In hepatocytes, the
increased load of free fatty acids is followed by an altered function
of mitochondria and endoplasmic reticulum, which ultimately
causes the release of reactive oxygen species. Moreover, though
indirect mechanisms, free fatty acids trigger the release of
pro-inflammatory cytokines, in particular interleukin-6 and
tumor-necrosis factor-α, which are both involved in the
pathogenetic mechanisms of GO. In support of an altered
inflammatory state in hypercholesterolemia as the possible cause
of the association between GO and high cholesterol, Busnelli
et al. reported that statins are protective in terms of systemic
inflammation in swine (80). Obviously, these explanations are
speculative and further investigations are required.
STRENGTHS AND LIMITATIONS
The observation of a protective role of statins in developing GO
in GD patients as well as the correlation of GO and its activity
with serum cholesterol are quite novel, and promising for a
possible use of statins in GO. On the other hand, the studies
available so fare are quite few, no randomized clinical trial are
available, because of which the role of statins, and of cholesterol
in GO must be considered still preliminary.
CONCLUSIONS
Both basic and clinical findings regarding the effects of statins
on GO are encouraging and deserve to be better investigated.
Whether statins have an intrinsic role or their effects are related
to their capability of lowering cholesterol has to be clarified.
Nevertheless, the relation between the presence and the activity
of GO and the levels of cholesterol in patients with GD and GO
of recent onset may have important clinical implications as they
may unravel a new field in GO management, and prompt the
necessity for investigating if lowering cholesterol is associated
with improved GO outcomes. If the data were confirmed, the
use of statins could be considered to improve the efficacy
of immunosuppressive therapy, maybe allowing to reduce GC
dosage of and consequently limiting their side effects. Clearly,
these are just speculations and further, possibly prospective
studies are needed.
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